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Abstract
Autobioluminescent cellular models are emerging tools for drug discovery that rely on
the expression of a synthetic, eukaryotic‐optimized luciferase that does not require an
exogenous chemical substrate to produce its resultant output signal. These models can
therefore self‐modulate their output signals in response to metabolic activity dynamics
and  avoid  the  sample  destruction  and  intermittent  data  acquisition  limitations  of
traditional  fluorescent  or  chemically  stimulated  bioluminescent  approaches.  While
promising for reducing drug discovery costs and increasing data acquisition relative to
alternative  approaches,  these  models  have  remained  relatively  untested  for  drug
discovery applications due to their recent emergence within the field. This chapter
presents a history and background of these autobioluminescent cellular models to offer
investigators a generalized point of reference for understanding their capabilities and
limitations and provides side‐by‐side comparisons between autobioluminescent and
traditional,  substrate‐requiring toxicology screening platforms for pharmaceutically
relevant three‐dimensional and high‐throughput screening applications to introduce
investigators to autobioluminescence as a potential new drug discovery toolset.
Keywords: luciferase, lux, toxicology, high‐throughput screening, three‐dimensional
cell culture, drug discovery
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1. Introduction to autobioluminescence
1.1. A brief overview of autobioluminescence
Autobioluminescence is defined as the ability of a cell to self‐initiate the production of a
luminescent signal using only endogenously supplied substrates to perform the enzymatic
reactions  necessary  for  signal  generation.  In  this  regard,  it  is  separate  from  traditional
bioluminescence in that it is not dependent on the exogenous addition of a chemical substrate
to supplement the metabolic cosubstrates that are naturally present within cells expressing an
associated luciferase protein. Interestingly, under this definition, there are many examples of
autobioluminescence in nature that can be found across a diverse array of organisms such as
bacteria, dinoflagellates, fungi, and beetles [1]. However, of these natural autobioluminescent
systems, only that of the bacteria (commonly referred to as the lux system) has been success‐
fully  transitioned  as  a  reporter  system  for  scientific  applications  while  maintaining  its
autonomous functionality [2–4].  The remaining systems, such as firefly luciferase, Renilla
luciferase, and Gaussia luciferase, have been limited in this transition by incomplete under‐
standings of the genetic frameworks behind their substrate production biochemical pathways
or limitations on the abilities of host cells to support the endogenous production of all the
components required for their expression. These systems therefore all require the external
application of a chemical substrate (d‐luciferin for firefly luciferase and coelenterazine for
Renilla and Gaussia luciferase) to activate their light production under scientifically relevant
applications [5].
Figure 1. The autobioluminescent reaction catalyzed by the bacterial luciferase gene cassette. The luciferase is formed
from a heterodimer of the luxA and luxB gene products. The aliphatic aldehyde is supplied and regenerated by the
products of the luxC, luxD, and luxE genes. The required oxygen and reduced riboflavin phosphate substrates are scav‐
enged from endogenous metabolic processes and the flavin reductase gene (frp) aids in reduced flavin turnover rates in
some species. Used with permission from [7] under a Creative Commons Attribution‐Noncommercial license.
The successfully transitioned bacterial lux system, alternatively, utilizes a characterized core
set of five genes, luxC, luxD, luxA, luxB, and luxE, to express both its luciferase enzyme (a dimer
formed by the luxA and luxB gene products) and its supporting transferase (luxD), reductase
(luxC), and synthetase (luxE) enzymes that supply the required aldehyde substrate from
natural cellular metabolic components. In addition, this reaction also requires the metabo‐
lites FMNH2 and O2 in order to function, producing a luminescent output at 490 nm and a
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reduced corresponding acid compound, FMN, and H2O as products [6] (Figure 1). Interest‐
ingly, despite the relatively straightforward organization of this system and the longstanding
elucidation of its individual components roles and genetic identities, there were significant
hurdles that needed to be overcome before it could be successfully transitioned for expression
in the mammalian systems that are required for drug discovery applications.
1.2. History of autobioluminescent cellular model development
Due to its bacterial origin, the lux cassette was formerly believed to function solely in pro‐
karyotic hosts, and thus was not considered a viable tool for diagnostic screening in human
cell lines [8]. This belief was due to the initial difficulty researchers encountered in coordinating
the temporal and spatial coexpression of the multiple lux genes, the thermoinstability of the
lux proteins at the mammalian optimal temperature of 37°C, and the limited availability of the
FMNH2 cosubstrate within human cells relative to their uncompartmentalized bacterial
counterparts. As a result of these initial difficulties, alternative bioluminescent systems became
more popular for use in drug discovery applications. In particular, firefly luciferase (luc) has
become the dominant bioluminescent imaging target for this application due to its single gene
expression requirement, high quantum yield, and favorable output signal wavelength of 562
nm [9].
However, despite the initial challenges associated with transitioning the bacterial lux system
into mammalian cells, significant progress was made over the years that would eventually lead
to the development of an optimized version of the system that could function reliably within
the human cellular microenvironment. The first major stepping stone in this process was the
expression of a functional luciferase heterodimer (luxAB) in the human kidney cell line HEK293
by Patterson et al. in 2005 [10]. This demonstration was particularly important because
Patterson and her colleagues were able to overcome the previous limitations of both spatial/
temporal coexpression and protein thermostability. Unlike previous work that had attempted
to coordinately express the genes using short protein linker sequences or individual promot‐
ers [11–16], Patterson et al. linked the luxA and luxB genes using an internal ribosomal entry
site (IRES) element to allow for expression of individual protein products from a single mRNA
transcript. Thermostability issues were overcome by using human codon optimized gene
sequences corresponding to the less utilized Photorhabdus luminescens bacterial system, which
allowed for higher levels of transgene expression of proteins with greater thermal tolerance
than those of the traditionally employed Aliivibrio fischeri (previously Vibrio fischeri) system [17].
Further advances were made to the lux system by Close et al. in 2010 that built heavily upon
the techniques developed by Patterson et al. [18]. This later work expanded the earlier IRES‐
based expression strategy to coexpress pairs of lux genes from individual promoters and divide
the expression of the genes across two plasmids. Most importantly, however, Close and his
colleagues were able to overcome the limitation of signal output strength imparted by the low
level of endogenously available FMNH2 by including a sixth gene (frp) that encoded for a flavin
reductase enzyme. This enzyme was able to rapidly recycle the oxidized FMN in the mam‐
malian cytosol into FMNH2, which increased light output to the point where it could be
visualized externally using commonly available detection equipment. This marked the first
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demonstration of autobioluminescence in a host system amenable to drug discovery applica‐
tions, however, the autobioluminescent output levels from this approach were significantly
lower than traditional bioluminescent systems and the use of multiple plasmids and large,
repetitive IRES element DNA sequences made the system difficult to work with on a molecular
biology level.
These difficulties were later overcome by Xu et al. in 2014, who re‐optimized the system for
expression from a single promoter and therefore allowed it to be expressed from a single
plasmid [19]. This approach, which substituted viral 2A elements in place of the previously
employed IRES elements, allowed the full autobioluminescent DNA cassette to be manipulated
as a single gene and significantly increased the signal output level to the point where it could
be detected from the low numbers of cells that are commonly used in high throughput
screening applications. Using the new expression format, Xu and her colleagues were able to
demonstrate the use of autobioluminescent reporters for tracking cellular metabolic dynamics,
population sizes, and promoter activation events, finally demonstrating the use of autobiolu‐
minescence for the same applications as traditional bioluminescent reporter systems [19, 20].
1.3. Comparison of autobioluminescent, traditional bioluminescent, and fluorescent optical
imaging approaches
Unlike alternative bioluminescent and fluorescent reporter systems, which have been widely
employed for drug discovery for many years, the autobioluminescent system is relatively
new and thus has not been used by as many investigators as have the traditional systems.
It is therefore important to briefly define the primary differences between these systems and
detail the advantages and disadvantages of each as potential optical imaging targets.
Fluorescent systems, with green fluorescent protein (gfp) being the most recognizable
example, are arguably the most familiar of the optical imaging approaches and have several
significant advantages in that they are small, single gene constructs that are simple to
introduce into cells, do not require chemical exposure or sample destruction to function, and
are available in a wide variety of excitation and emission wavelengths to suit individual
assay needs [21]. Their primary drawback is that their requisite excitation signals can result
in autofluorescent background signals from the cells or subjects under study, often requiring
specialized equipment to filter out undesired light in order to acquire the resultant emission
signal [22]. In addition, complications can arise from the prolongation of fluorescent protein
activity after transcription has been stopped (enzymatically or through cell death) and
phototoxicity to host cells, yielding inaccurate readings in toxicity or metabolic activity
assays.
Bioluminescent reporters, on the other hand, express high signal‐to‐noise ratios due to the near
absence of natural bioluminescent production from host tissues and can be sourced from a
variety of different organisms with different substrates and output wavelengths to allow for
reporter multiplexing within a single system. However, similar to fluorescent reporters, the
luciferase proteins can remain active following genetic downregulation or cell death. In
addition, the introduction of the activating chemical substrate has the potential to unexpect‐
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edly influence the cellular system under study and requires the destruction of the sample to
efficiently interact with the genetically expressed luciferase [23].
Autobioluminescent reporters somewhat bridge these two systems by combining the favorable
high signal‐to‐noise ratios of traditional bioluminescent systems and the nondestructive nature
of the fluorescent systems. However, while their reliance on only endogenously produced
substrates eliminates concerns over phototoxicity or substrate interference, it also reduces their
total bioluminescent output levels relative to chemically stimulated systems. In addition, there
is currently only a single variant, and thus only a single output signal wavelength, available
for use [24]. Therefore, in the absence of a system that overcomes all limitations, investigators
must weigh the pros and cons of each approach to determine which is the most appropriate
for gathering their required data.
2. The use of autobioluminescent cellular models for high throughput
compound screening
2.1. Advantages of autobioluminescent cellular models for high throughput screening
Despite their output limitations relative to chemically stimulated bioluminescent systems,
autobioluminescent cellular models are particularly well suited for cytotoxicity assays and tier
I drug development screening because of their ability to endogenously synthesize and
regenerate the luminogenic substrates and cofactors (FMNH2 and O2) required for light
production. This autonomous signal production potential eliminates costly reagents and
minimizes the complexity of traditional assays formats, offering a simplified and cost‐effective
high throughput approach that reduces hands‐on human interaction and error. In practice, the
inherent high signal‐to‐noise ratio of the autobioluminescent signal is able to overcome the
relatively reduced total output flux to allow these models to function similarly to their
chemically stimulated counterparts [19, 25, 26]. This provides a significant advantage for their
use in in vitro high throughput viability assays, which have traditionally been fluorescence
based and are complicated by high background interference from cellular heme compounds
and tissue culture supplements [26–29]. This reduction in background has allowed autobio‐
luminescent cellular models to be applied as counterscreens for identifying false positives in
assays with notoriously high background effects, as was recently demonstrated in a study to
assess the rate of false positives in a fluorescence‐based assay for detecting the Alzheimer's‐
implicated Tau protein [30].
While this low background advantage is shared by traditional bioluminescent cellular models,
the unstimulated production of light that is unique to the autobioluminescent system provides
an additional advantage in that it allows for longitudinal data acquisition without sample
destruction. The presence of a continuous output signal that can represent real‐time metabolic
activity dynamics offers enhanced temporal resolution for assaying the cytotoxicity of
therapeutic compounds in high throughput screening formats and provides for standardiza‐
tion without the need to tailor each assay to the unknown kinetics of novel compounds [19].
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The typical chemically stimulated, bioluminescent‐based in vitro high throughput screening
assay requires an average of five sacrificial time points to generate sufficient data for under‐
standing the cytotoxicity of a compound. To take advantage of the full throughput capacity of
a 1536‐well plate, this requires the preparation, treatment, and processing of 7680 samples.
However, the nondestructive nature of the autobioluminescent testing format reduces these
sample requirements to only a single plate (1536 samples), which can then be imaged repeat‐
edly at each time point. This eliminates the generation, maintenance, and treatment of 6144
samples over the course of a typical assay, and thus greatly reduces financial costs while
increasing the convenience and quality of kinetic data collection.
2.2. Previously published examples of autobioluminescent cellular models for high
throughput screening
Because of the reduction in cost and complexity and increase in data acquisition afforded by
continuous imaging, autobioluminescent cellular models are becoming increasingly employed
as tools for early stage therapeutic compound cytotoxicity screening. Recently, researchers at
the National Institutes of Health performed a competitive evaluation of autobioluminescent
and commonly applied ATP content, alamarBlue, CyQUANT, and MTS metabolic activity
assays using a multi‐time point study approach and reported that the IC50 data of known
cytotoxic compounds were consistent across each system [25]. In this comparison, the contin‐
uous data output of the autobioluminescent cellular models was specifically investigated by
comparing a single sample set against individually prepared sample sets that were sacrificed
at each time point, and it was determined that repeated assessment of a single sample
correlated well with the individually prepared samples of the alternative assays.
More in‐depth comparisons have also been performed that contrasted the use of autobiolu‐
minescent and chemically stimulated bioluminescent reporter systems to assess the pharma‐
cological effects of compounds on human cellular models in vitro. In this evaluation, the
autobioluminescent models were compared with a chemically stimulated bioluminescent ATP
content assay following exposure of cells to the Library of Pharmacologically Active Com‐
pounds (LOPAC), which contains 1280 compounds known to possess pharmacologically
active effects on human tissues. When deployed in a high throughput 1536‐well format, the
IC50 data from the autobioluminescent cellular models yielded a strong correlation to the
results of the ATP assay (R2 = 0.7847), but with the added strength of allowing for kinetic
monitoring, thus showcasing its power as a biomonitoring tool for cell toxicity and compati‐
bility with high throughput conditions. While this study focused on the HEK293 human
kidney cell line, the same advantages should remain applicable in more medically relevant
drug screening models as well [19].
2.3. Incorporation of autobioluminescent cellular models into existing drug discovery
workflows
Although it has not been the primary focus of any previously published autobioluminescent
work, an interesting observation from the existing literature is that autobioluminescent
cellular models can often be substituted into existing bioluminescent and fluorescent assay
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workflows without significant changes to the original assay protocols. This interoperability
results from the similarity of the autobioluminescent output signal to those from the
chemically simulated bioluminescent systems for which the protocols and existing detection
equipment were originally designed. Because in both cases the output signals are light in the
visible wavelength, the only major considerations when switching between systems have
been the variation in output signal intensity and the necessary imaging parameter adjust‐
ments needed to achieve minimum signal detection thresholds. This minimizes the level of
hardware optimization required to shift between assay modalities in both in vitro and in vivo
imaging protocols.
A review of the literature suggests that the primary method for optimizing minimum signal
detection thresholds during this transition has been to employ larger numbers of cells to
overcome the difference in signal output between chemically stimulated and autobiolumines‐
cent systems. In autobioluminescent systems, signal detection has been demonstrated from
population sizes down to 20,000 cells/well in a 24‐well plate format, and from as few as 25,000
cells following subcutaneous injection into a mouse model [18]. While these are significantly
larger numbers of cells than are required for chemically stimulated bioluminescent systems,
the low background associated with bioluminescence has nonetheless been shown to retain
sufficient sensitivity for use in whole‐animal imaging experiments [28, 31]. It is important to
note, however, that in some cases the use of increased cell numbers is not possible, such as for
studies specifically focused on very small numbers of cells, such as early stage colonizing
tumors. In these scenarios, the primary optimization employed must focus on adjustment of
the imaging parameters, such as the use of longer acquisition times or increased luminescent
pixel binning sizes.
3. Correlating the data output of autobioluminescent cellular models to
classical assay formats
Since the generation of autobioluminescence relies upon the cell's capability to express the
synthetic bacterial luciferase cassette as well as the availability of endogenous metabolites
(e.g., O2 and FMNH2) for the synthesis of the required substrates, the autobioluminescent light
output of these models correlates very strongly with the overall cellular metabolic activity
level. As such, autobioluminescent cellular models represent excellent indicators for cytotox‐
icity following exposure to a compound of interest. Unlike conventional cytotoxicity assays
that often require cellular destruction concurrent with data acquisition, autobioluminescent
cellular models continuously self‐modulate their light output in response to metabolic activity
dynamics across the full lifetime of the host, thus allowing for the noninvasive visualization
of metabolic activity at any time point throughout the entire exposure period. As a result, the
nondestructive autobioluminescence assay generates more data similar to that obtained by
traditional assays while simultaneously reducing the number of samples and investigator
interaction time required per run. As an example of these capabilities, a side‐by‐side compar‐
ison between an autobioluminescent HEK293 cell model and the classic 3‐(4,5‐dimethylthia‐
zol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) cytotoxicity assay was performed over a 96‐
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hour exposure period. In this evaluation, the autobioluminescent model system demonstrated
similar toxicity response data across the full set of compound exposure concentrations, and
correlated strongly with the MTT assay (R2 = 0.9262 at 96‐hour postexposure) (Figure 2A).
Similarly, a strong correlation (R2 = 0.9163) was obtained between the autobioluminescent
model system and an ATP content‐based CellTiter‐Glo cytotoxicity assay at 48‐hour postex‐
posure (Figure 2B). Although all these assays performed very similarly, it is important to note
that the MTT and CellTiter‐Glo assays both required individual sample sets to be prepared
for each time point, whereas the substrate‐free nature of the autobioluminescent cellular
model system allowed for repeated monitoring of the same sample populations over time.
Figure 2. Correlating the data output of an autobioluminescent cellular model to alternative assay formats. (A) side‐by‐
side comparison of the autobioluminescent model system output signal and the MTT cytotoxicity assay output for
HEK293 cells exposed to 200–1000 μg/ml of Zeocin for 96 hours. (B) correlation of the relative viabilities of Zeocin‐
treated HEK293 cells as measured by autobioluminescence (x‐axis) relative to those determined by the chemically
stimulated bioluminescent CellTiter‐Glo ATP content assay (y‐axis). Each data point represents treatment with a
unique dose of Zeocin. Relative viability was expressed as a percentage of the corresponding assay reading from un‐
treated control cells. (C) correlation of the relative viabilities of Zeocin‐treated HEK293 cells as measured by autobiolu‐
minescence (x‐axis) relative to the chemically stimulated bioluminescent GSH‐Glo glutathione concentration assay (y‐
axis). (D) treatment with 200–1000 μg/ml Zeocin resulted in an increase in reactive oxygen species levels in HEK293
cells that was not correlated to Zeocin concentration nor autobioluminescent output.
Furthermore, it was possible to leverage the nondestructive nature of the autobioluminescent
HEK293 model to multiplex the real‐time cytotoxicity assay with other downstream assays in
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order to further elucidate the specific toxicity pathways that were activated. To illustrate this
application, following evaluation for metabolic activity by autobioluminescent output, the
cells were then immediately assayed to measure intracellular glutathione levels using a GSH‐
Glo assay or for the presence of reactive oxygen species using a ROS‐Glo assay. In these
evaluations, the GSH‐Glo and ROS‐Glo assays, respectively, identified a reduction in gluta‐
thione concentration and an increase in reactive oxygen species level, indicating oxidative
stress. However, only the reduction in glutathione concentration was determined to be dose
responsive, and correlated with the reduction in autobioluminescent output with an R2 value
of 0.8462 across the full range of compound exposure concentrations (200–1000 μg/ml)
(Figure 2C). In contrast, reactive oxygen species levels were not observed to correlate with
either the test compound concentrations or the autobioluminescent output (Figure 2D).
4. Variability of autobioluminescent responses resulting from system
expression in different cellular hosts
4.1. Demonstrated autobioluminescent cellular model systems
Thus far, only four autobioluminescent cellular models have been demonstrated: human
kidney cells (HEK293) [10, 18], human liver cells (HepG2), immortalized breast cancer cells (T‐
47D) [19, 32], and colorectal cancer cells (HCT116) [19]. The most well documented of these
models has been the HEK293 cell line, which underwent validation by the National Institutes
of Health as a pharmaceutical screening tool [25]. Less documentation is available for the T‐
47D, HepG2, and HCT116 cell lines; however, an analysis of their previous use has indicated
that their average autobioluminescent output levels are lower than that of their autobiolumi‐
nescent HEK293 counterpart [19], likely due to differences in their basal metabolic activity
levels. Nonetheless, the signals from these alternative models have proven to be easily
detectable [19], and their tumorigenic lineage has made them useful beyond the straightfor‐
ward toxicology/metabolic activity screening applications that have emerged as the primary
role for the autobioluminescent HEK293 model.
In particular, the autobioluminescent T‐47D model has found utility as a biomonitor for the
detection of endocrine disruptor activity due to its natural proliferative rate increase following
estrogenic compound exposure. Since estrogenic compounds are defined by their stimulation
of cell reproduction, this model has been harnessed to assay for increases in autobiolumines‐
cent output as a function of cellular proliferation to track a compound's ability to function as
an endocrine disruptor using automated imaging equipment [19, 32]. In this role, autobiolu‐
minescent T‐47D cells were shown to exhibit output signals proportional to their total popu‐
lation size (R2 = 0.99) across a large dynamic range, suggesting that this model is appropriate
for estimating the changes in population size stimulated by estrogenic responses. When
challenged with picomolar concentrations of the prototypical estrogenic chemical, 17β‐
estradiol, a dose‐dependent autobioluminescent response similar to traditional cell prolifera‐
tion assays was observed [33]; however, contrary to the classical estrogenicity screens that
require sample destruction, the autobioluminescent endocrine disruptor detection assay
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maintained its trademark benefit of continuous data collection without sample sacrifice. This
made the platform an efficient and universal screening system that offered the continuous
detection of both cell toxicity and estrogenicity without the additional reagent costs tradition‐
ally associated with assay multiplexing.
4.2. Variability of autobioluminescent responses across differential cellular models
Because the autobioluminescent phenotype is closely related to the metabolic activity level of
the host cell expressing the synthetic bacterial luciferase cassette, it is possible that significant
variances in signal output potential can exist among available cellular models. This concern is
compounded by the nascent state of the technology, which has limited the number of cellular
hosts documented in the literature and made it difficult to determine how consistent the
reporter signal output strength will be upon expression in previously untested cell lines or
tissues. The uncertainty surrounding this variability is concerning given that choosing an
appropriate cellular model is particularly crucial in drug discovery applications where the
same compound can exert variable toxicological responses in different cell lines or tissue types
[34]. Due to the lack of published data on this topic, experiments were performed to compare
the autobioluminescent responses of the HEK293, T‐47D, and HepG2 cell lines following
exposure to the common chemotherapeutic agent doxorubicin. Due to the nondestructive,
continuous nature of these autobioluminescent cellular models, it was possible to track the
impact of doxorubicin exposure on metabolic activity dynamics over a 72‐hour exposure
period. In this example, a typical sigmoidal dose response was observed from the HEK293 cells
at each assay time point with an estimated IC50 value of 2 × 10−8 M (20 nM) at 72‐hour postex‐
posure (Figure 3A). However, doxorubicin treatment at concentrations higher than 5 × 10−7 M
(500 nM) reduced autobioluminescent output by more than 95% within 72 hours of treatment.
In contrast, both the T‐47D and HepG2 models were less susceptible to doxorubicin than the
HEK293 cells, and neither produced a sigmoidal dose response (Figure 3B and C). For these
models, autobioluminescence reductions of greater than 95% were only observed by 72 hours
following the start of doxorubicin treatment at concentrations ≥ 5 μM, whereas treatment with
concentrations lower than 20 nM resulted in less than a 10% reduction in autobioluminescence
output. Interestingly, however, doxorubicin treatment at 500 nM and 1 μM induced an increase
Figure 3. Variability of autobioluminescent dynamics in response to doxorubicin treatment across different cellular
models. (A) autobioluminescent HEK293 cells displayed a sigmoidal dose‐response curve in response to doxorubicin
treatment at 24, 48, and 72 hours posttreatment. In contrast, neither (B) T‐47D nor (C) HepG2 cells produced similar
autobioluminescent responses to doxorubicin treatment over the course of the exposure period.
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in autobioluminescent output in both the T‐47D and HepG2 models over the course of the
exposure period, with a peak at 48‐hour posttreatment. These differential autobioluminescent
responses are hypothesized to be the result of the varying cellular metabolic background
activities and differential gene expression patterns exerted by each cell's activated toxicity
pathways, thus demonstrating a clear emphasis on the importance of choosing a cellular model
with an appropriate metabolic background for each specific application.
5. The use of autobioluminescent cellular models for three‐dimensional
cell culture applications
5.1. Common three‐dimensional scaffold materials for in vitro drug discovery assays
Under natural in vivo conditions, cells reside in three‐dimensional (3D) structures that are
formed predominantly through attachment to an extracellular protein matrix. Partially
through this attachment, the cells monitor and react to their immediate environment to
modulate basic processes such as proliferation, morphology, and gene and protein expression,
among other behaviors [35–37]. While in some cases, the natural proliferation rates and native
phenotypes of the cells are retained under traditional monolayer culture conditions, more often
their observed behavior and physiology become altered and are no longer representative of
their natural in vivo characteristics [38]. In contrast, cells cultured in naturally derived or
synthetically produced in vitro 3D culture systems have been demonstrated to better recapit‐
ulate in vivo cellular phenomena [39, 40]. Therefore, modern in vitro drug discovery platforms
are increasingly taking advantage of synthetic 3D culture scaffolds to induce cellular growth
under more in vivo‐like conditions in order to improve the efficiency of novel compound
development [41–43].
This transition has provided investigators with a variety of different 3D cell culture scaffold
materials to choose from, many of which differ vastly in composition and, therefore, appropri‐
ateness to specific culture conditions. Collagen, a ubiquitous, naturally occurring protein
polymer, has become frequently used for generalized in vitro 3D culture systems. The adapta‐
bility of collagen allows it to be used either on its own, as a hydrogel in which cells are suspended
and then eventually attach to and remodel, or as a proteinaceous coating on other substrates [44].
Similar to collagen, other naturally occurring protein (e.g., fibrin or silks) and polysaccharide
(e.g., chitin or hyaluronic acid) polymers have also been used alone, or in blends, to structure
3D cellular matrices [45] and affect cellular activities [46, 47]. In addition to these proteins, other
natural materials such as corals have found utility as scaffolding for bone tissue engineering [48],
as well as decellularized tissues repopulated with different cell types [49].
Synthetic polymers such as polycaprolactone, a comparatively basic example that is biode‐
gradable and commonly used in medical applications, have also been widely applied toward
3D cell culture [50]. These synthetic 3D culture materials are becoming a popular option for
in vitro drug discovery platforms due to their ability to be embedded with growth factors [51],
specialized with functional groups, or studded with small molecules [52]. This generally offers
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investigators more options for tailoring the physical characteristics of the final scaffold, such
as fiber traits, meshed patterns, sponge surface area, void volume, and more precise control of
the final physical design.
5.2. The advantages of autobioluminescent systems for cellular screening in three‐
dimensional cell culture applications
Both fluorescent and bioluminescent imaging systems are easily employed for interrogating
cellular structures and activities in traditional monolayer cultures, but the utility of both is
handicapped within 3D cell culture systems [26, 53]. Fluorescent reporters are limited primar‐
ily by the materials used in 3D culture systems, most of which display high levels of auto‐
fluorescence as the scaffold material responds to the excitation signal, or in some cases, to the
presence of ambient light [54]. This effect manifests as strong background noise that can
completely eclipse the desired signal and is especially prevalent for collagen or collagen‐coated
scaffolds, which display autofluorescence around 420–460 nm [54]. Further compounding the
use of fluorescent technologies in 3D culture are the effects of phototoxicity and photobleach‐
ing. The repeated bombardment of samples with excitation photon energy has been shown to
increase the prevalence of reactive oxygen species, which in turn can damage cellular compo‐
nents and skew assay results to the point where the cells may no longer be representative of
their true in vivo state [55, 56]. Photobleaching, on the other hand, occurs when the fluorescent
reporter is destroyed by the input photon energy and is no longer available to release photons.
This attenuates the output signal and diminishes assay sensitivity, resulting in potential data
misinterpretation. In addition to these cellular concerns, the 3D cell culture scaffold itself can
also interfere with excitation by presenting a physical barrier to photon excitation at the interior
of a construct that can be tens to hundreds of micrometers thick. To compensate for this,
investigators must apply increased excitation intensities or durations to reach acceptable
signal‐to‐noise ratios, which in turn increase the prevalence of autofluorescence, phototoxicity,
and photobleaching.
Because of these multiple hurdles to using fluorescent reporters in 3D culture systems,
bioluminescence has become more prevalent as an imaging system under these conditions [54,
57]. However, traditional chemically stimulated bioluminescent systems are similarly limited
by the tendency of the 3D scaffold material to induce heterogeneous substrate distribution.
Unlike monolayer cultures, where the activating chemical can be evenly distributed to all cells
in a population, the presence of the 3D scaffold material, and the variations in construct size,
cell density, and matrix configuration across the scaffold, results in the uneven distribution of
the activating chemical and its required cosubstrates [58]. Consequently, cells on the exterior
of the scaffold have more efficient access to the activating chemical than those on the interior
and therefore can initiate a luminescent signal with altered timing and kinetics. This can lead
to ambiguous bioluminescent measurements across the population of cells under study and
misrepresentations of the true state of the system [36].
Unlike these fluorescent and chemically stimulated bioluminescent systems, autobiolumi‐
nescent cellular models produce their luminescent signals independent of any external
stimulation, and therefore are not subject to limitations imposed by activating chemical
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diffusion dynamics, excitatory photon penetration, or phototoxicity and photobleaching. As
a result, every cell in the population is continuously producing an autobioluminescent signal
representative of its current metabolic activity level. Therefore, even if an asymmetric
autobioluminescent signal is measured from a 3D construct, that distribution itself is of
significant value to the investigator because it is an objective report on a cell's state at any
given position in the construct. The primary physical limitation to the use of autobiolumi‐
nescent cellular models within 3D culture conditions is the physical absorption and dispersion
of the autobioluminescent signal as it interacts with the structural material. As with the
alternative systems, this can be mediated through the selection of amenable scaffolding
material or by increasing signal acquisition times in order to obtain increased photon counts,
although it cannot be completely eliminated as it is a fundamental limitation of the use of 3D
structures within the culture system itself.
5.3. Using autobioluminescent cellular models to elucidate metabolic activity and drug
responsiveness in monolayer and three‐dimensional culture systems
The choice between a traditional monolayer and a 3D cell culture platform can strongly
influence the basal metabolic activity of the cells under study. In monolayer formats, the
metabolic state of the cells is constantly in flux as they are continuously passaged until
senescence. In contrast, cells seeded into a natural or synthetic 3D scaffold may proliferate
initially but, over time, their growth rate will slow and they will enter a stabilized metabolic
equilibrium [42, 59]. This growth format is more representative of the cells’ natural state, as
their proliferation rates, morphology, and gene expression more closely resemble their in vivo
states [41–43, 60]. However, the use of a 3D culture system does not guarantee faithful
replication of in vivo‐like conditions, as the 3D scaffold itself, through traits such as matrix
stiffness or construct dimensions, can induce hypoxia at levels that differ significantly from
those observed in vivo [61, 62]. These cases often better model tumor biology than healthy
tissues, with the 3D construct mimicking a necrotic center with a proliferative exterior and a
range of metabolic states in between [63]. Therefore, the direct comparison of metabolic activity
levels (whether under a steady state, during proliferation, or throughout viability transitions)
between scaffold types, traditional monolayer cultures, and in vivo cells can be complicated
and should be made while considering factors like nutrient gradients, surface area, cell density,
and relative perfusion rates, among many others.
Given the contrasting metabolic conditions between monolayer and 3D cell culture systems,
autobioluminescent cellular models are uniquely positioned to assess cellular health in ways
other imaging modalities cannot. Since autobioluminescent cells produce light as a function
of their individual metabolic state without a dependence on externally supplied activating
chemicals or excitatory photon stimulation, cross‐platform comparisons can be performed
with limited uncontrollable variability and using sample preparation scales that are logistically
tractable. Indeed, an investigation of these contrasts using autobioluminescent HEK293 cells
seeded onto polycaprolactone 3D culture scaffolds demonstrated a higher proliferation rate
and basal metabolic activity level than when an identical number of cells was seeded and
grown in monolayers on polystyrene plates or in suspension culture [64]. Similarly, when a
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range of cellular concentrations were either plated in monolayers or encapsulated in collagen
hydrogels and examined for autobioluminescence, only the output signals from the collagen‐
encapsulated 3D cultures remained tightly correlated with the initial cell density measure‐
ments after 48 hours of incubation. This suggests that, compared to traditional monolayer
culture approaches, collagen‐encapsulated 3D culture allows for longer term measurements
of a wide range of cell population sizes.
Further interrogation indicated that the differences in basal metabolic levels induced by
scaffold composition were significant enough to influence how the cells responded to xenobi‐
otic challenges [42, 65], demonstrating that these emerging methods of 3D culture and
adequate tools for evaluating cellular health are essential to modern drug discovery models.
These results were not limited to only a single cell type, as breast, pancreatic and colon cancer
cellular models all showed alterations to their proliferation and metabolic rates in the presence
of stiffer 3D matrices, and were consequently found to be less sensitive to paclitaxel and
gemcitabine treatment [62]. This was corroborated through a direct interrogation of collagen‐
encapsulated autobioluminescent HEK293 cells, which were observed to be more resistant to
treatment with a metabolic inhibitor relative to their monolayer‐grown counterparts. Together,
these examples demonstrate how in vitro 3D culture alters cell behavior relative to traditional
culture methods, and how investigators can use 3D culture variables to create better 3D models
for drug discovery.
5.4. The use of autobioluminescent cellular models for continuous cellular tracking within
three‐dimensional culture scaffolds
Unlike fluorescent and chemically stimulated bioluminescent cellular models that require
repeated, invasive stimulatory inputs to activate their output signals, autobioluminescent
cellular models are amenable to continuous monitoring and dynamic metabolic activity
tracking because their autobioluminescent output signals are continuously active. The on‐
demand availability and noninvasive nature of this output therefore makes these models
highly amenable to repeated or continuous monitoring approaches that are not feasible with
the traditional systems due to logistical or economical concerns. This offers significant utility
for tumor xenograft tracking, which has traditionally relied upon repeated activating chemical
injections, photonic stimulations, or physical measurements to track tumor volume, all of
which are invasive and subject to large read‐to‐read variation [66, 67]. Autobioluminescent
cellular models, in contrast, allow for low variation, high‐resolution cellular tracking and
viability monitoring.
As a demonstration of their utility for continuous monitoring, autobioluminescent HEK293
models have been grown on 3D polycaprolactone scaffolds and measured continuously for 24
hours via repeated light output measurements taken at 15‐minute intervals using an automat‐
ed system. Similarly, using magnetic‐based 3D culture approaches, these same models have
been monitored repeatedly for experiments lasting up to 45 days without the need to sacrifice
samples or concerns related to sample‐to‐sample variability [64]. When employed in more
complex in vitro 3D and xenograft models, the continuous signal generation of the autobiolu‐
minescent cellular models can be leveraged to provide data that was not previously obtainable,
Special Topics in Drug Discovery14
such as monitoring cell detachment from 3D constructs to model tumor metastasis. This
approach has significant value for therapeutic and regenerative medicine applications, where
tracking stem cells after implantation is currently difficult to implement, but critical for model
development [68]. In this application, autobioluminescent stem cell models could be employed
to continuously monitor the site of implantation for changes in cell number or health. Then,
from within the same sample or animal subject, sloughed cells could be visualized at peripheral
sites, such as the brain, because the cells remain autobioluminescent. This approach would
offer significant advantages over chemically stimulated bioluminescent systems, whose
activating chemicals cannot be evenly distributed to all tissues and are restricted from the brain
by the blood‐brain barrier.
6. Advantages of autobioluminescent cellular models for assaying the
metabolic effects of nontraditional stressors
The autobioluminescent system's ability to initiate and self‐modulate its signal generation
without cellular destruction or exogenous substrate input gives it the ability to function fully
intracellularly, which is significantly different than the majority of in vitro bioluminescent
assays that employ the presence of intracellular metabolites, usually in the form of ATP, to act
as a limiting reagent for supporting the bioluminescent production of an exogenously applied
luciferase and excess required alternative cosubstrates. Functionally, this means that autobio‐
luminescent systems can be utilized to monitor the metabolic activity or population size
dynamics of specific community members in heterogeneous cocultures. This ability was
recently investigated using cocultures of autobioluminescent HEK293 cells and virulent
Escherichia coli O157:H7 to study the metabolic effects of bacterial infection and better under‐
stand the mechanism and timing of E. coli O157:H7 infection to improve treatment options for
exposed patients [20].
In the course of this study, the autobioluminescent cellular system was compared to two other
bioluminescence assays, the ATP‐dependent CellTiter‐Glo metabolic activity assay and the
ROS‐Glo hydrogen peroxide‐dependent reactive oxygen species assay, in order to determine
the most reliable method for assessing E. coli O157:H7 infection. Through the course of this
evaluation, it was determined that the destructive assays were significantly influenced by the
liberated metabolites from the co‐lysed E. coli O157:H7 cells, which resulted in inflated
readings due to overexposure of the exogenously supplemented luciferase reporter to the
liberated bacterial metabolites. While the ATP‐dependent CellTiter‐Glo assay counterintui‐
tively showed an increase in metabolic activity concurrent with cellular death, raising from
58.4% of uninfected control cell bioluminescence at 2‐hour postinfection (hpi) to 70.8% by 4
hpi, the autobioluminescent system was self‐limited to reporting only on the metabolic
dynamics of the targeted human cellular population, which were shown to decrease from
11.2% of control cell autobioluminescence at 2 hpi to 2.5% by 4 hpi. Similar results were
observed in comparisons between the autobioluminescent cellular model and the ROS‐Glo
assay, although no significant differences in reporter function were observed when uninfected
control cells were compared across all three reporter systems [19, 25].
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Using the autobioluminescent cellular model, the investigators were able to determine the
minimum bacterial population threshold required to induce reductions in host cell metabolic
activity to between 5 × 105 and 1 × 106 colony forming units. Additionally, the authors were
able to leverage the nondestructive nature of the autobioluminescent cellular model to monitor
the ability of the host cells to recover from E. coli O157:H7 infection by tracking metabolic
activity continuously as the infecting bacteria were removed and antibacterial compounds
were applied. This analysis allowed them to conclude that the host cells could return to normal
metabolic activity within 2 hours of bacterial clearance, even after infections were allowed to
reduce the basal metabolic activity of the cells to 2.6% of the untreated control cells. This study
serves as a demonstrative example of the way that the autobioluminescent system can be
applied to obtain data that would not be logistically or economically feasible to obtain using
traditional chemically stimulated bioluminescent systems due to the large number of samples,
significant hands‐on time, and high reagent costs that would be required.
7. Expression of autobioluminescence using alternative host systems
Although not directly relevant to drug discovery, it is nonetheless important to note the
significantly larger body of autobioluminescent work that has been performed in nonhuman
model systems. Because the autobioluminescent gene cassette used for this work is the same
as the one used for human cellular expression, only with alternative supporting genetic
elements and codon optimization, it is highly likely that the techniques developed in these
alternative models will eventually make their way into the autobioluminescent human cellular
models as well. Based on historical development patterns, it is likely that the most impending
modification to be constructed will be a chemically activated promoter system for compound‐
specific activation of autobioluminescent output. This approach has been used in both bacterial
and yeast‐based autobioluminescent models to assess transcriptional activity from reporter
system‐fused promoters [69], to monitor autobioluminescently tagged populations in the
environment [70], and to detect environmental pollutants for bioremediation [71, 72].
The classical examples of this system are the Saccharomyces cerevisiae‐based autobioluminescent
estrogen (BLYES) [4] and androgen (BLYAS) [73] detection strains. These strains do not produce
any signal in the absence of their activating signals, but can self‐initiate luciferase expression
in response to compound detection through the use of estrogen and androgen response
elements, respectively. Their use of autobioluminescence as a reporter allows them to respond
substantially faster than the traditional lacZ‐based colorimetric screens, offering detectable
autobioluminescence within 1–6 hours of exposure [73] compared to the 24‐hour performance
period of alternative lacZ‐based reporter systems [74]. Although no drug discovery assays
using this expression strategy have yet been reported in human cellular systems, the ability to
initiate autobioluminescent production in response to promoter activation has been demon‐
strated, suggesting that these model formats are on the horizon [19].
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8. Conclusions
Although autobioluminescent cellular models are a new technology, they have emerged as
promising tools for drug discovery. Their ability to reduce the number of required sample
preparation steps and reagent requirements for existing assay formats positions them well to
lower assay costs, while their high signal‐to‐noise ratios can allow them to fill the nondestruc‐
tive imaging gaps left by fluorescent systems with complicating levels of background
autofluorescence. Similarly, their natural compatibility to work within complex 3D culture
systems should, at least in the near term, make them robust against the upcoming shift toward
this growth system for early stage compound evaluation. However, their ultimate utility as
drug discovery tools will rely on their adoption by the investigators routinely performing these
assays. Without widespread use, and therefore sufficient validation within the field, it will be
difficult for these models to take hold regardless of the advantages they offer.
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